Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4494058 | 0.84 | SIGMAR1 (0.55) | SIGMAR1SLC6A2SLC6A4CYP3A4CYP2D6 | |
| SCHEMBL5752131 | 0.78 | SIGMAR1 (0.53) | SIGMAR1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL7296899 | 0.76 | SIGMAR1 (0.61) | SIGMAR1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4492195 | 0.76 | SIGMAR1 (0.54) | SIGMAR1CYP3A4 | |
| SCHEMBL2268114 | 0.74 | SIGMAR1 (0.58) | SIGMAR1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL11338768 | 0.74 | SIGMAR1 (0.58) | SIGMAR1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL27914058 | 0.74 | CYP3A4 (0.68) | SIGMAR1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL16011794 | 0.73 | SLC6A3 (0.63) | SIGMAR1SLC6A3 | |
| SCHEMBL7409590 | 0.73 | SIGMAR1 (1.00) | SIGMAR1SLC6A2SLC6A4SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL8627527 | 0.73 | MEN1 (0.58) | SIGMAR1SLC6A2SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-5574031-A | Piperazine carboxamides | PHARMACIA AKTIEBOLAG (SE) | 1996-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | SIGMAR1 409/4885SLC6A2 3677/4885SLC6A4 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.